Citizens Rates Taysha Gene Therapies (TSHA) buy, $11 Price Target

Citizens analyst Silvan Tuerkcan reiterated a Market Outperform rating on Taysha Gene Therapies, Inc. (TSHA) on June 23, 2026. The firm kept its price target at $11.00, reflecting a positive outlook on the clinical-stage biotechnology company. This rating comes as the stock trades on the NasdaqGS exchange, where it was priced at $6.94 on Tuesday.

Analysts Set New Price Targets

The decision by Citizens to stick with its $11.00 target follows a period of active adjustments by other Wall Street firms. On June 23, 2026, Citizens actually lifted its target from $8.00 to $11.00 while maintaining its Market Outperform stance. Other analysts shared this optimism around the same time. BMO Capital maintained an Outperform rating and raised its target from $10.00 to $14.00, while B of A Securities increased its target from $9.00 to $10.00 on June 23, 2026. Later that month, Baird maintained an Outperform rating and bumped its target to $15.00, and Needham reiterated a Buy rating with a $12.00 target on June 30, 2026. More recently, Goldman Sachs maintained a Buy rating on July 21, 2026, with a $13.00 target, and Wolfe Research initiated coverage with an Outperform rating on September 17, 2026.

Taysha Stock Performance and Market Position

The stock has shown some strength recently, trading above its 50-day moving average of $5.78 and its 200-day moving average of $5.48. With a market capitalization of approximately $1.64 billion, the company is valued at a premium relative to its current revenue, which is common for biotech firms in the clinical testing phase. The current share price of $6.94 is well above the 52-week low of $2.87, though it remains below the $13.00 average target price suggested by the 13 analysts covering the stock.

Recent Earnings Data

In its most recent financial reports, Taysha Gene Therapies reported revenue of $5.49 million. The company is not yet profitable, which is typical for businesses focusing on drug development; it reported a loss of $0.41 per share and a negative return on equity of 47.06%. However, the company maintains a high level of liquidity to fund its research, evidenced by a current ratio of 17.77. The next earnings report is scheduled for November 4, 2026.

About Taysha Gene Therapies

Taysha Gene Therapies is a Dallas-based biotech firm that creates gene therapies for rare diseases affecting the central nervous system. They use a specific type of viral vector to deliver genetic material to patients' cells. Their main projects focus on treating severe conditions like Rett syndrome and giant axonal neuropathy. Because the company is still testing these treatments in clinical trials, analyst ratings often hinge on data updates from these studies.

What's Ahead for Taysha Gene Therapies, Inc.

Investors will likely watch for further clinical updates and the upcoming financial results in November to see if the company can meet the growth expectations set by analysts. While the $11.00 target from Citizens suggests potential for the stock to rise, these projections are based on current data and analyst assumptions about the company's future drug pipeline success.